Member Info for Matml74

Hi Liam, No they will need to be given the data from SNG. The EMA don't have access to the data just the company and its partners (Parexel etc). One readout occurs I presume EMA will get the data but likely not before the US.

Presentation was great. Big year coming up with rfq's to be decided over next 2 qrt's.

Ridiculous statement. Auto royalties will increase significantly through the year.

Based on last years results they provided more detail than that and also commented on the Q1 trading post results so hopefully we get some extra detail tomorrow.

Sector is definitely down big time. Appreciate your work Floater!

FTSE AIM all share index is up 10% since beginning of the year. That would be a fair comparison to make rather than selecting individual shares. Maybe focussing on relevant sector would be more applicable.

Some of us have been in for many years SPY. It is OK to disagree with the methods of a CEO, particularly when you have seen the same thing done better elsewhere!!

What did he do wrong? Placing into a year low in an already low sentiment market for gold stocks. There has been ample opportunity this year to place at a higher level and it may have put a base into the SP. If they are telling me they could not foresee a need for funding until this late in the year they need a new CFO. His excuse that there were no opportunities is bull**** in my opinion.

He should take a note of how the SEE placement went last night (another Aussie AIM midcap), placing into a near year high getting many bluechip and industry partners onboard..... two days prior to an AGM! Oh the directors couldn't buy because it was a closed period but they did right buy the shareholders.

I initially thought that may be the case like so many other placings Brockwl. But this placing has also comes with a $120m order from Magna..... and a $1.1billion RFQ pipeline that the company is confident will will a ‘significant’ proportion of.

If it goes anywhere near 11p it is load up time.

Agree totally WF. Why did the raise need to be done so quickly? No reason for that as far as I can see. Too many things with this raise still leaving sour taste in the mouth even after SD's interview.

Berenberg printing an article saying the company was fully funded on Proactive whilst preparing the fundraise stinks to high heaven.

But it's done now. The target is now on the CEO's back to get this share price moving northwards. He needs to be given the time now to do that.

Might be better off asking the question on the AZN board since they actually make the vaccine ........

A few things to remember when trying to work out chances of success. Synairgen are able to skew their chances of success in the P3 trial design in a number of ways.

• they get to select the type of patients they want (ie the breathless, of which they have plenty of data to show the drug works particularly well with these patients through multiple trials)
• that get to determine what the primary endpoints and secondary endpoints are (based on previous trial successes).
• they are able to apply their preferred analyses to the data sets (this was determined from the P2 results -see the P2 lancer paper)

So basically, based on 20 years of research, trials and understanding the type of patients and settings that SNG001 is likely to give the best outcome the company is able to design a trial knowing that chances of success are high. P2 trials are really where pharma companies work out whether the drug is a ‘dud’ or not. P3 trials are hugely expensive and ‘big pharma’ don’t get big by wasting P3 money on duds.

Most P3 clinical trials fail due to poor trial design. Parexel have a good article about this on their website if anyone wants to understand why P3 trials can fail. Good trial design stacks the odds in the favour of success.

It’s a an unusual paper out of Romania that is based solely around SNG001. Was submitted for peer review in July. Romania had 4 or 5 locations as part of the P3 and I think they were quite quick to get trial sites set up so maybe these hospitals had some links to the university researchers who have put this paper together.

The market is pricing in a higher risk of SNG001 failing in either its P3 trials or in its ability to get its product to market than you or I or polygon or any other person that is currently invested here...... but therein lies the opportunity.

99.99% of people have never heard of Synairgen so its not unexpected, but if successful with their P3 results the whole world will know exactly who this company is and then there will be a desperate scramble for shares.

Very slightly. About 0.25%

Jerry, I have been involved and a very large number of placings. I understand the mechanisms and have seen them all. There are many ways to skin a cat but this way was always going to **** off PI's. Simple. Does it make any difference long term. No. But SD just made his job a little harder in the short term.

Jerry, Seeing Machines raised £20m last September at a premium to it's SP. This could have been done very easily with the asset this company has.

I am hugely supportive of this company, its assets and its team but questions do need to be asked about the way this was done.

Exactly. If the funds were needed to sure up the balance sheet for finance agreements then say that. That is not the reason or it would have been spelt out in the placing doc.

With only £6m in the bank funds were needed to strengthen the balance sheet and be able to adequately fund 2022 exploration. I get that completely.

The real issue here is this fund raise could have been done at a much higher level and wasn't. This erodes trust in the CEO for me, and I have backed him the whole way. To build up so much goodwill over the last few months with PI's through his excellent engagement he will need to start that process all over again.

Yes this is particularly good when it seems around 2/3rd's of the recruitment into Sprinter occurred once Delta variant was prevalent in many of the countries where the trial was being undertaken.

Well Sean Day certainly has put the pressure on himself to provide this ‘value’ for shareholders he has been talking about. I think he will have 12 months max to turn this SP around from what will be lows around 14p otherwise his head will be on the block.

Whilst I don’t have any issues with the company raising money (that is why the company is listed after all) this placing is somewhat galling at this level when there has been ample opportunities to place at a higher level...... but it has been obvious to anyone that has watched this share closely over the last 10 months that Berenberg have been forcing this down to this level.

Lastly it was very naive for SD to buy in this placing having resisted buying on the open market all year. He had just managed to get many private investors on his side through excellent engagement and more many this will feel like a stab in the back ensuring he gets himself a discounted purchase.

The hole has been dug, can he climb his way out!